Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Biosynthesis in Bacteria01:24

Biosynthesis in Bacteria

1.0K
Biosynthesis in bacteria is a fundamental anabolic process that generates essential macromolecules, including proteins, nucleic acids, lipids, and polysaccharides. These macromolecules are critical for cellular growth, replication, and function. The process is tightly regulated and energetically linked to catabolic pathways to ensure optimal resource utilization.Biosynthetic pathways begin with precursor metabolites such as pyruvate, acetyl-CoA, and glucose-6-phosphate derived from glycolysis,...
1.0K
Biosynthesis of Polysaccharides01:26

Biosynthesis of Polysaccharides

984
Polysaccharides such as glycogen and starch are synthesized from nucleoside diphosphate sugars, primarily uridine diphosphate glucose (UDPG) and adenosine diphosphate glucose (ADPG). These activated glucose donors act as key intermediates in carbohydrate metabolism and biosynthesis. UDPG primarily involves glycogen synthesis in animals and many bacteria, while ADPG plays a fundamental role in starch synthesis in plants and certain bacteria.UDPG is formed when glucose-1-phosphate reacts with...
984
Amino Acid Biosynthetic Pathways01:29

Amino Acid Biosynthetic Pathways

1.8K
Amino acid biosynthesis is essential for cell growth, protein synthesis, and metabolic regulation. Cells generate essential and non-essential amino acids from metabolic intermediates to sustain vital biological functions. These intermediates originate from key metabolic pathways: glycolysis, the tricarboxylic acid (TCA) cycle, and the pentose phosphate pathway. Important precursors include α-ketoglutarate, pyruvate, oxaloacetate, phosphoenolpyruvate, and erythrose-4-phosphate, which...
1.8K
Bioreactor Controls-III01:22

Bioreactor Controls-III

67
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
67
Production of Antibiotics01:27

Production of Antibiotics

265
Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
265

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Neurology·2003
Same author

Design and expression of polymeric immunoglobulin fusion proteins: a strategy for targeting low-affinity Fcgamma receptors.

Protein expression and purification·2001
Same author

Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis.

Archives of neurology·2001
Same author

Interactions between the sympathetic nervous system and the immune system.

Brain, behavior, and immunity·1999
Same author

Treatment of multiple sclerosis with interferon beta.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·1999
Same author

Cytokine secretion by deltagamma and alphabeta T cells in monophasic experimental autoimmune encephalomyelitis.

Journal of autoimmunity·1999
Same journal

Dupilumab Emerges as an Effective Antibody Therapy for Eosinophilic Esophagitis.

Annual review of medicine·2026
Same journal

CAR T Cell Toxicities and Emerging Treatment Strategies.

Annual review of medicine·2026
Same journal

Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape.

Annual review of medicine·2026
Same journal

Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.

Annual review of medicine·2026
Same journal

Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management.

Annual review of medicine·2026
Same journal

Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium.

Annual review of medicine·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

A Pleural Effusion Model in Rats by Intratracheal Instillation of Polyacrylate/Nanosilica
03:32

A Pleural Effusion Model in Rats by Intratracheal Instillation of Polyacrylate/Nanosilica

Published on: April 12, 2019

6.7K

Immunologic therapy of multiple sclerosis.

B G Arnason1

  • 1Department of Neurology, Pritzker School of Medicine, Chicago, Illinois, USA. barnason@drugs.bsd.uchicago.edu

Annual Review of Medicine
|March 12, 1999
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) treatments like interferon beta and Copaxone reduce relapses and disease activity. These therapies help manage MS, making it a treatable condition with reduced disability accumulation.

More Related Videos

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
11:07

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

25.7K
Noninvasive Intratracheal Lipopolysaccharide Instillation in Mice
04:10

Noninvasive Intratracheal Lipopolysaccharide Instillation in Mice

Published on: March 31, 2023

6.9K

Related Experiment Videos

Last Updated: May 5, 2026

A Pleural Effusion Model in Rats by Intratracheal Instillation of Polyacrylate/Nanosilica
03:32

A Pleural Effusion Model in Rats by Intratracheal Instillation of Polyacrylate/Nanosilica

Published on: April 12, 2019

6.7K
Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
11:07

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

25.7K
Noninvasive Intratracheal Lipopolysaccharide Instillation in Mice
04:10

Noninvasive Intratracheal Lipopolysaccharide Instillation in Mice

Published on: March 31, 2023

6.9K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Current treatments aim to reduce disease activity and manage symptoms.
  • Interferon beta preparations and Copaxone are established therapies for relapsing-remitting MS.

Purpose of the Study:

  • To evaluate the efficacy of interferon beta preparations (Betaseron, Avonex, Rebif) and Copaxone in treating relapsing-remitting multiple sclerosis.
  • To assess the impact of these treatments on disease burden and activity.
  • To determine the effect of Betaseron on disability progression in secondary progressive MS.

Main Methods:

  • Review of clinical trial data for interferon beta (Betaseron, Avonex, Rebif) and Copaxone.
  • Assessment of attack frequency reduction.
  • Evaluation of disease burden using T2-weighted MRI.
  • Measurement of disease activity via gadolinium-enhanced MRI scans.
  • Analysis of disability accumulation in secondary progressive MS patients treated with Betaseron.

Main Results:

  • Interferon beta preparations reduced MS attack frequency by 30% and major attacks significantly.
  • Disease burden on MRI was markedly lessened, with over 80% reduction in disease activity shown by gadolinium-enhanced MRI.
  • Copaxone also reduced MS attack frequency by 30% and disease activity on MRI.
  • Betaseron demonstrated a reduction in disability accumulation for secondary progressive MS patients.

Conclusions:

  • Interferon beta and Copaxone are effective treatments for relapsing-remitting multiple sclerosis.
  • These therapies significantly reduce clinical relapses and MRI-measured disease activity.
  • Betaseron offers benefits in slowing disability progression in secondary progressive MS.
  • Multiple sclerosis is now considered a treatable disease with available therapeutic options.